Vell Biologics is led by an experienced leadership team with decades of combined expertise in building and scaling rare-disease and serious chronic-disease businesses across India and the Middle East.
Our strength lies in translating scientific innovation into meaningful patient access. Through deep capabilities in regulatory strategy, market access, medical affairs, commercialisation, institutional engagement, and patient-support programmes, we understand what it takes to bring specialised therapies to patients in complex and underserved markets.
With an asset-light, access-led commercial model, we collaborate with global innovators to address four critical healthcare gaps: Awareness, Accessibility, Availability, and Affordability.
Vell Biologics is led by an experienced leadership team with decades of combined expertise in building and scaling rare-disease and serious chronic-disease businesses across India and the Middle East.
Our strength lies in translating scientific innovation into meaningful patient access. Through deep capabilities in regulatory strategy, market access, medical affairs, commercialisation, institutional engagement, and patient-support programmes, we understand what it takes to bring specialised therapies to patients in complex and underserved markets.
With an asset-light, access-led commercial model, we collaborate with global innovators to address four critical healthcare gaps: Awareness, Accessibility, Availability, and Affordability.
To accelerate the availability of global innovations by partnering with world-class manufacturers,navigating complex regulatory paths, and ensuring equitable access for every patient who needs
advanced therapies.
- Reduce time-to-market for critical biologics and rare-disease therapies.
- Build a sustainable access ecosystem by integrating awareness, affordability, and availability.
- Expand partnerships across India, the GCC, and South-East Asia with a patient first approach.
- Enable institutions and governments to adopt high-impact treatments through scientific and operational excellence.
- Patient Access: Deliver availability, affordability, and continuous treatment support.
- Partnerships: Collaborate with global innovators to bring advanced biologics to underserved markets.
- Regulatory Strength: Ensure streamlined dossier readiness, compliance, and fast market entry across India and the GCC.
- Scientific Excellence: Maintain strong medical, safety, and quality frameworks for responsible launch and scale-up.
- Awareness & Education: Strengthen early diagnosis and treatment adoption through clinician engagement and programs.
